...
VCYTMID

Veracyte, Inc.

HealthcareBiotechnology
$36.27
$0.02(+5.40%)
52W$22.61
$50.71
FinancialsValuationvs CAI
Updated Mar 5, 12:00 AM
RSI40
RS Rating59/99
Beta1.12
Volatility55%
F-Score8/9
Mkt Cap$2.9B
CONSOLIDATING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

CONSOLIDATING

Veracyte, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 59), indicating performance broadly in line with the market. Earnings growth of 7% provides fundamental context to the price action. Investors should exercise caution due to high volatility (55% annualized), which requires wider risk management.

Relative Strength
59
out of 99
Average
Trend Score
2/4
Minervini Criteria
CONSOLIDATING
Risk (Beta)
1.12
vs S&P 500
ABOVE MKT
52W Position
49%
from 52W low
Lower Half
Trend & Momentum Analysis

Trend Template (Minervini)

CONSOLIDATING2/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$39.60
50 SMA > 100 SMA$40.05
100 SMA > 150 SMA$36.96
150 SMA > 200 SMA$34.36

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$36.11+0.44%ABOVE
50 SMA$39.60-8.42%BELOW
100 SMA$40.05-9.44%BELOW
150 SMA$36.96-1.86%BELOW
200 SMA$34.36+5.56%ABOVE

Price Performance

1D+5.4%
1W-6.4%
1M+4.0%
3M-18.7%
6M+11.8%
YTD-14.4%
1Y+10.0%
3Y+15.2%
52-Week Trading Range49% from low
$36.27
52W Low$22.61
52W High$50.71

Technical Indicators

RSI (14)BEARISH
39.9
305070
VCP ScoreCOOL
4/10
Base depth: 36.6%

Risk Profile

Beta
1.12
52W Vol
55%
ATR
$1.61
Max DD (1Y)
-34%

Volume Analysis

Today
931.5K
50D Avg
806.8K
Vol Ratio
1.15x
Liquidity
MODERATE

Earnings Momentum

Q1'25+540%
$0.09
Q2'25-118%
$-0.01
Q3'25+26%
$0.24
Q4'25+733%
$0.50
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+26.44%
5 Years:+34.50%
3 Years:+20.37%
TTM:+16.01%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+171.83%

Stock Price CAGR

10 Years:+18.45%
5 Years:-5.26%
3 Years:+15.19%
1 Year:+10.04%

Return on Equity

10Y Avg:-19.1%
5Y Avg:-2.6%
3Y Avg:0.2%
Last Year:5.1%

Key Metrics

Market Cap$2.9B
Gross Margin70.1%
Net Margin12.8%
Piotroski F-Score8/9

More VCYT Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

VCYT vs CAICAIADPTNAUTCDIO

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 59 meansVCYT outperformed 59% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.12 means 12% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 8/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 4/10 with COOL status.

Frequently Asked Questions

Is VCYT in an uptrend right now?

VCYT has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.

Is VCYT overbought or oversold?

VCYT's RSI (14) is 40. The stock is in neutral territory, neither overbought nor oversold.

Is VCYT outperforming the market?

VCYT has a Relative Strength (RS) Rating of 59 out of 99. VCYT is performing about average compared to the market.

Where is VCYT in its 52-week range?

VCYT is trading at $36.27, which is 72% of its 52-week high ($50.71) and 49% above its 52-week low ($22.61).

How volatile is VCYT?

VCYT has a Beta of 1.12 and 52-week volatility of 55%. It's more volatile than the S&P 500 - expect bigger swings.